Clinical Trial Update: A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 open-label study evaluating autologous CAR-T therapies DSG3-CAART and CABA-201 for active pemphigus vulgaris; the trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pemphigus Vulgaris

Drugs mentioned

• CABA-201
• DSG3-CAART (Desmoglein 3 Chimeric Autoantibody Receptor T Cells)

Snippet

Sponsor: Cabaletta Bio | Conditions: Pemphigus Vulgaris | Phase 1, Phase 2 | Status: RECRUITING